BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26959643)

  • 1. Alterations in the mir-15a/16-1 Loci Impairs Its Processing and Augments B-1 Expansion in De Novo Mouse Model of Chronic Lymphocytic Leukemia (CLL).
    Kasar S; Underbayev C; Hassan M; Ilev I; Degheidy H; Bauer S; Marti G; Lutz C; Raveche E; Batish M
    PLoS One; 2016; 11(3):e0149331. PubMed ID: 26959643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of mir-15a/16-1 in early B cell development in a mouse model of chronic lymphocytic leukemia.
    Underbayev C; Kasar S; Ruezinsky W; Degheidy H; Schneider JS; Marti G; Bauer SR; Fraidenraich D; Lightfoote MM; Parashar V; Raveche E; Batish M
    Oncotarget; 2016 Sep; 7(38):60986-60999. PubMed ID: 27533467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice.
    Raveche ES; Salerno E; Scaglione BJ; Manohar V; Abbasi F; Lin YC; Fredrickson T; Landgraf P; Ramachandra S; Huppi K; Toro JR; Zenger VE; Metcalf RA; Marti GE
    Blood; 2007 Jun; 109(12):5079-86. PubMed ID: 17351108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia.
    Kasar S; Underbayev C; Yuan Y; Hanlon M; Aly S; Khan H; Chang V; Batish M; Gavrilova T; Badiane F; Degheidy H; Marti G; Raveche E
    Oncogene; 2014 Jun; 33(25):3307-15. PubMed ID: 23995789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity.
    Salerno E; Scaglione BJ; Coffman FD; Brown BD; Baccarini A; Fernandes H; Marti G; Raveche ES
    Mol Cancer Ther; 2009 Sep; 8(9):2684-92. PubMed ID: 19723889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The New Zealand black mouse as a model for the development and progression of chronic lymphocytic leukemia.
    Salerno E; Yuan Y; Scaglione BJ; Marti G; Jankovic A; Mazzella F; Laurindo MF; Despres D; Baskar S; Rader C; Raveche E
    Cytometry B Clin Cytom; 2010; 78 Suppl 1(Suppl 1):S98-109. PubMed ID: 20839343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic in vivo lentiviral delivery of miR-15a/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemia.
    Kasar S; Salerno E; Yuan Y; Underbayev C; Vollenweider D; Laurindo MF; Fernandes H; Bonci D; Addario A; Mazzella F; Raveche E
    Genes Immun; 2012 Feb; 13(2):109-19. PubMed ID: 21881595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Murine models of chronic lymphocytic leukaemia: role of microRNA-16 in the New Zealand Black mouse model.
    Scaglione BJ; Salerno E; Balan M; Coffman F; Landgraf P; Abbasi F; Kotenko S; Marti GE; Raveche ES
    Br J Haematol; 2007 Dec; 139(5):645-57. PubMed ID: 17941951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.
    Klein U; Lia M; Crespo M; Siegel R; Shen Q; Mo T; Ambesi-Impiombato A; Califano A; Migliazza A; Bhagat G; Dalla-Favera R
    Cancer Cell; 2010 Jan; 17(1):28-40. PubMed ID: 20060366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential roles of miR-15a/16-1 and miR-497/195 clusters in immune cell development and homeostasis.
    Hutter K; Rülicke T; Drach M; Andersen L; Villunger A; Herzog S
    FEBS J; 2021 Mar; 288(5):1533-1545. PubMed ID: 32705746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of MiR-15a and MiR-16-1 as prognostic biomarkers in chronic lymphocytic leukemia.
    Braga TV; Evangelista FCG; Gomes LC; Araújo SSDS; Carvalho MDG; Sabino AP
    Biomed Pharmacother; 2017 Aug; 92():864-869. PubMed ID: 28599250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy.
    Cutrona G; Matis S; Colombo M; Massucco C; Baio G; Valdora F; Emionite L; Fabris S; Recchia AG; Gentile M; Neumaier CE; Reverberi D; Massara R; Boccardo S; Basso L; Salvi S; Rosa F; Cilli M; Zupo S; Truini M; Tassone P; Calabrese M; Negrini M; Neri A; Morabito F; Fais F; Ferrarini M
    Leukemia; 2017 Sep; 31(9):1894-1904. PubMed ID: 28053325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia.
    Veronese A; Pepe F; Chiacchia J; Pagotto S; Lanuti P; Veschi S; Di Marco M; D'Argenio A; Innocenti I; Vannata B; Autore F; Marchisio M; Wernicke D; Verginelli F; Leone G; Rassenti LZ; Kipps TJ; Mariani-Costantini R; Laurenti L; Croce CM; Visone R
    Leukemia; 2015 Jan; 29(1):86-95. PubMed ID: 24732594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia.
    Ferrajoli A; Shanafelt TD; Ivan C; Shimizu M; Rabe KG; Nouraee N; Ikuo M; Ghosh AK; Lerner S; Rassenti LZ; Xiao L; Hu J; Reuben JM; Calin S; You MJ; Manning JT; Wierda WG; Estrov Z; O'Brien S; Kipps TJ; Keating MJ; Kay NE; Calin GA
    Blood; 2013 Sep; 122(11):1891-9. PubMed ID: 23821659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression.
    Wang M; Tan LP; Dijkstra MK; van Lom K; Robertus JL; Harms G; Blokzijl T; Kooistra K; van T'veer MB; Rosati S; Visser L; Jongen-Lavrencic M; Kluin PM; van den Berg A
    J Pathol; 2008 May; 215(1):13-20. PubMed ID: 18348159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility alleles for aberrant B-1 cell proliferation involved in spontaneously occurring B-cell chronic lymphocytic leukemia in a model of New Zealand white mice.
    Hamano Y; Hirose S; Ida A; Abe M; Zhang D; Kodera S; Jiang Y; Shirai J; Miura Y; Nishimura H; Shirai T
    Blood; 1998 Nov; 92(10):3772-9. PubMed ID: 9808571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression.
    Santanam U; Zanesi N; Efanov A; Costinean S; Palamarchuk A; Hagan JP; Volinia S; Alder H; Rassenti L; Kipps T; Croce CM; Pekarsky Y
    Proc Natl Acad Sci U S A; 2010 Jul; 107(27):12210-5. PubMed ID: 20566844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.
    Bresin A; Callegari E; D'Abundo L; Cattani C; Bassi C; Zagatti B; Narducci MG; Caprini E; Pekarsky Y; Croce CM; Sabbioni S; Russo G; Negrini M
    Oncotarget; 2015 Aug; 6(23):19807-18. PubMed ID: 26090867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia.
    Sampath D; Liu C; Vasan K; Sulda M; Puduvalli VK; Wierda WG; Keating MJ
    Blood; 2012 Feb; 119(5):1162-72. PubMed ID: 22096249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of miR-15a and miR-16-1 in patients with chronic lymphocytic leukemia.
    Humplikova L; Kollinerova S; Papajik T; Pikalova Z; Holzerova M; Prochazka V; Divoka M; Modriansky M; Indrak K; Jarosova M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Dec; 157(4):284-93. PubMed ID: 24026141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.